Interesting non-operative approach for T1-2, N0-1, M0 TNBC or HER2+ breast cancer, 58 patients enrolled in this single center phase II out of MDA. 62% of patients had CR on biopsy after systemic therapy, if results hold true over a longer follow-up period this may be of significant impact.
Thought provoking retrospective study regarding primary RPLND for stage II NSGCT. Study found that after RPLND N1-3 disease had a recurrence rate of about 20%, which flattens at years 2 to 5, and in patients who recurred all were treated successfully with chemotherapy. Adjuvant chemotherapy is preferred on the NCCN for post-RPLND patients who are pN2-N3, however this suggests close surveillance may be an option in centers with high surgical expertise.
The combination of venetoclax and 5-azacitidine (5-AZA) for older or unfit patients with acute myeloid leukemia (AML) improves remission rates and survival compared with 5-AZA alone.
Suddenly met-NSCLC is a crowded space. This study did not conclude that T+D+CT was better than D+CT, the findings showed that D+CT was better than CT alone. The addition of T to D+CT improved the PFS and OS trend but I don’t think this was a homerun result. There was not a significant OS benefit and further follow-up will declare these results. Also an improved outcomes were not seen in the non-squamous population. The pembrolizumab studies have 5+ years of follow-up and an improvement in PFS and OS across NSCLC subtypes.
Supportive care trial though negative. No role for high dose steroids here.
A radiation oncology article, would like to hear comments from our colleagues regarding this, It seems the trend in rad onc that shorter course is better.
This is not a randomized study, results though can not be ignored since ibrutinib is less toxic than many of the treatments used.
A benign hematology article, not a large study but an eye opener.
Another prognostic marker that can predict added efficacy of therapy in this case bevacizumab.
Coming soon to a pharmacy near you?